Trial · NCT03336333
Adverse events951
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 951
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 41 | 227 | 65 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 1: Zanubrutinib Without Del(17p) | 11 | 240 | 12 |
| other | Anaemia | Blood and lymphatic system disorders | Cohort 2: Zanubrutinib With Del(17p) | 5 | 111 | 7 |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 7 | 227 | 12 |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 1: Zanubrutinib Without Del(17p) | 1 | 240 | 1 |
| other | Leukopenia | Blood and lymphatic system disorders | Cohort 2: Zanubrutinib With Del(17p) | 0 | 111 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 101 | 227 | 233 |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 1: Zanubrutinib Without Del(17p) | 30 | 240 | 62 |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort 2: Zanubrutinib With Del(17p) | 13 | 111 | 28 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 30 | 227 | 62 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 1: Zanubrutinib Without Del(17p) | 8 | 240 | 15 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Cohort 2: Zanubrutinib With Del(17p) | 4 | 111 | 4 |
| other | Palpitations | Cardiac disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 3 | 227 | 3 |
| other | Palpitations | Cardiac disorders | Cohort 1: Zanubrutinib Without Del(17p) | 10 | 240 | 10 |
| other | Palpitations | Cardiac disorders | Cohort 2: Zanubrutinib With Del(17p) | 3 | 111 | 3 |
| other | Vertigo | Ear and labyrinth disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 2 | 227 | 4 |
| other | Vertigo | Ear and labyrinth disorders | Cohort 1: Zanubrutinib Without Del(17p) | 9 | 240 | 12 |
| other | Vertigo | Ear and labyrinth disorders | Cohort 2: Zanubrutinib With Del(17p) | 2 | 111 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 1: Bendamustine + Rituximab Without Del(17p) | 12 | 227 | 13 |
| other | Abdominal pain | Gastrointestinal disorders | Cohort 1: Zanubrutinib Without Del(17p) | 11 | 240 | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03336333/events